Moreover, several clinical studies have demonstrated that hepatic CD36 expression is higher in biopsy-proven NAFLD patients compared to subjects with histologically normal liver94,120,121. This evidence concerns the gene CD36 and metabolic dysfunction-associated steatotic liver disease.